# LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT06479759** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 50 (estimated)

## Conditions studied

- NSCLC
- PD-1

## Interventions

- **DRUG:** LM-108 antibody and sintilimab
- **DRUG:** LM-108 antibody and sintilimab and chemotherapy

## Key facts

- **NCT ID:** NCT06479759
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-12
- **Primary completion:** 2025-06-12
- **Final completion:** 2025-12-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479759, "LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06479759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*